bictegravir/emtricitabine/tenofovir alafenamide (TBC)


Original post, click here

Generic Name: bictegravir/emtricitabine/tenofovir alafenamide

Brand Name: TBC

Manufacturer: Gilead Sciences Canada, Inc.

Indications: HIV-1 infection

Manufacturer Requested Reimbursement Criteria1:

​For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults.

Submission Type: New Combination

Project Status: Pending

Call For Patient Input: April 2, 2018

Patient Input Closed: May 22, 2018

Anticipated Date: April 30, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Tags

infectious diseases, hiv/aids